Last reviewed · How we verify
AB154
At a glance
| Generic name | AB154 |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (PHASE2)
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (PHASE3)
- Switch Maintenance in Pancreatic (PHASE1, PHASE2)
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PHASE3)
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (PHASE3)
- AB154 Combined With AB122 for Recurrent Glioblastoma (EARLY_PHASE1)
- Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AB154 CI brief — competitive landscape report
- AB154 updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI